Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial - Concepedia

Concepedia

Publication | Closed Access

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial

488

Citations

0

References

1994

Year

Charles J. Fisher, Gus J. Slotman, Steven M. Opal, John P. Pribble, Roger C. Bone, George Emmanuel, David P. Ng, Duane C. Bloedow, Michael A. Catalano

Critical Care Medicine

Abstract

This initial evaluation suggests that human recombinant IL-1ra is safe and may provide a dose-related survival advantage to patients with sepsis syndrome. A larger, definitive clinical trial is needed to confirm these findings.